-
Je něco špatně v tomto záznamu ?
Distinct Responsiveness of Tumor-Associated Macrophages to Immunotherapy of Tumors with Different Mechanisms of Major Histocompatibility Complex Class I Downregulation
A. Piatakova, I. Polakova, J. Smahelova, SD. Johari, J. Nunvar, M. Smahel
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
GA19-00816S
Grantová Agentura České Republiky
CZ.02.1.01/0.0/0.0/16_019/0000785
European Regional Development Fund
CZ.1.05/2.1.00/19.0395
European Regional Development Fund
SVV 260568
Univerzita Karlova v Praze
LM2018126
Ministerstvo Školství, Mládeže a Tělovýchovy
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
34205330
DOI
10.3390/cancers13123057
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Tumor-associated macrophages (TAMs) plentifully infiltrate the tumor microenvironment (TME), but their role in anti-tumor immunity is controversial. Depending on the acquired polarization, they can either support tumor growth or participate in the elimination of neoplastic cells. In this study, we analyzed the TME by RNA-seq and flow cytometry and examined TAMs after ex vivo activation. Tumors with normal and either reversibly or irreversibly decreased expression of major histocompatibility complex class I (MHC-I) molecules were induced with TC-1, TC-1/A9, and TC-1/dB2m cells, respectively. We found that combined immunotherapy (IT), composed of DNA immunization and the CpG oligodeoxynucleotide (ODN) ODN1826, evoked immune reactions in the TME of TC-1- and TC-1/A9-induced tumors, while the TME of TC-1/dB2m tumors was mostly immunologically unresponsive. TAMs infiltrated both tumor types with MHC-I downregulation, but only TAMs from TC-1/A9 tumors acquired the M1 phenotype upon IT and were cytotoxic in in vitro assay. The anti-tumor effect of combined IT was markedly enhanced by a blockade of the colony-stimulating factor-1 receptor (CSF-1R), but only against TC-1/A9 tumors. Overall, TAMs from tumors with irreversible MHC-I downregulation were resistant to the stimulation of cytotoxic activity. These data suggest the dissimilarity of TAMs from different tumor types, which should be considered when utilizing TAMs in cancer IT.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21024535
- 003
- CZ-PrNML
- 005
- 20211013133903.0
- 007
- ta
- 008
- 211006s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers13123057 $2 doi
- 035 __
- $a (PubMed)34205330
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Piatakova, Adrianna $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 252 50 Vestec, Czech Republic
- 245 10
- $a Distinct Responsiveness of Tumor-Associated Macrophages to Immunotherapy of Tumors with Different Mechanisms of Major Histocompatibility Complex Class I Downregulation / $c A. Piatakova, I. Polakova, J. Smahelova, SD. Johari, J. Nunvar, M. Smahel
- 520 9_
- $a Tumor-associated macrophages (TAMs) plentifully infiltrate the tumor microenvironment (TME), but their role in anti-tumor immunity is controversial. Depending on the acquired polarization, they can either support tumor growth or participate in the elimination of neoplastic cells. In this study, we analyzed the TME by RNA-seq and flow cytometry and examined TAMs after ex vivo activation. Tumors with normal and either reversibly or irreversibly decreased expression of major histocompatibility complex class I (MHC-I) molecules were induced with TC-1, TC-1/A9, and TC-1/dB2m cells, respectively. We found that combined immunotherapy (IT), composed of DNA immunization and the CpG oligodeoxynucleotide (ODN) ODN1826, evoked immune reactions in the TME of TC-1- and TC-1/A9-induced tumors, while the TME of TC-1/dB2m tumors was mostly immunologically unresponsive. TAMs infiltrated both tumor types with MHC-I downregulation, but only TAMs from TC-1/A9 tumors acquired the M1 phenotype upon IT and were cytotoxic in in vitro assay. The anti-tumor effect of combined IT was markedly enhanced by a blockade of the colony-stimulating factor-1 receptor (CSF-1R), but only against TC-1/A9 tumors. Overall, TAMs from tumors with irreversible MHC-I downregulation were resistant to the stimulation of cytotoxic activity. These data suggest the dissimilarity of TAMs from different tumor types, which should be considered when utilizing TAMs in cancer IT.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Polakova, Ingrid $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 252 50 Vestec, Czech Republic
- 700 1_
- $a Smahelova, Jana $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 252 50 Vestec, Czech Republic
- 700 1_
- $a Johari, Shweta Dilip $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 252 50 Vestec, Czech Republic
- 700 1_
- $a Nunvar, Jaroslav $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 252 50 Vestec, Czech Republic
- 700 1_
- $a Smahel, Michal $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 252 50 Vestec, Czech Republic
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 12 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34205330 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20211006 $b ABA008
- 991 __
- $a 20211013133900 $b ABA008
- 999 __
- $a ind $b bmc $g 1708361 $s 1145032
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 13 $c 12 $e 20210619 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a GA19-00816S $p Grantová Agentura České Republiky
- GRA __
- $a CZ.02.1.01/0.0/0.0/16_019/0000785 $p European Regional Development Fund
- GRA __
- $a CZ.1.05/2.1.00/19.0395 $p European Regional Development Fund
- GRA __
- $a SVV 260568 $p Univerzita Karlova v Praze
- GRA __
- $a LM2018126 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- LZP __
- $a Pubmed-20211006